News Archive - Page 3 of 27 - SMA Europe

The purpose of SMA Europe is to provide a framework to stimulate collaboration and accelerate translational research pathways in SMA and promote patient care.

  1. Novel protective gene for SMA opens new therapeutic options

    The research group of Prof. Dr. Brunhilde Wirth, Head of the Institute of Human Genetics at the University Hospital Cologne and Chair of our Scientific Advisory Board, succeeded to identify calcineurin-like EF-hand Protein 1 (CHP1) reduction as a novel protective modifier for SMA. The results of this study have been published in Brain, an international highly renowned journal. […]


  2. Our 2018 – 2020 activities and initiatives

    In April this year, a new 2-year strategy was set and a new working structure established. Our new structure   Elections Presidency: Mencía de Lemus from our Spanish organisation, FundAME vice-Presidency: Nicole Gusset from our Swiss organisation, SMA Schweiz Treasury: Inge Schwersenz from our German organisation, DGM     Executive Committee As SMA Europe continues to grow, it […]


  3. An animation to explain lumbar punctures

    A lumbar puncture, also called spinal tap, is a medical test. It may be applied to children and young people in order to diagnose diseases of the nervous system or to give a medication (such as Spinraza™). The department of Paediatric Neurology and Muscle Diseases at Freiburg University Medical Centre has produced this animation to […]


  4. Roche ends development of olesoxime

    It was announced today that Roche has taken the difficult decision of ending the development of neuro-protective compound Olesoxime. In 2016 Roche started the OLEOS study, an open label extension study evaluating the long term safety and effectiveness of olesoxime. Many discussions with Health Authorities (FDA and EMA) and SMA experts were had and the […]